PIK3CA Activating Mutation in Colorectal Carcinoma: Associations with Molecular Features and Survival

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Rosty, Christophe ^a,b,c   Young, Joanne P ^a,b   Walsh, Michael D ^a,d   Clendenning, Mark ^a   Sanderson, Kristy ^a   Walters, Rhiannon J ^a   Parry, Susan ^e,f   Jenkins, Mark A ^g   Win, Aung Ko ^g   Southey, Melissa C ^g   Hopper, John L ^g   Giles, Graham G ^g,h   Williamson, Elizabeth J ^g   English, Dallas R ^g,h   Buchanan, Daniel D ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Envoi Pathology   (Australia)

^d Sullivan and Nicolaides Pathology ^*  (Australia)

^e MIDDLEMORE HOSPITAL   (New Zealand)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4 BISPHOSPHATE;

AGED; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PIK3CA GENE; PREVALENCE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EXONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84879001702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065479     Document Type: Article

References (43)

1. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, et al. (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317: 239-242.
2. Bader AG, Kang S, Vogt PK, (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103: 1475-1479.
3. Furnari FB, Huang HJ, Cavenee WK, (1998) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58: 5002-5008.
4. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
5. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
6. Guo XN, Rajput A, Rose R, Hauser J, Beko A, et al. (2007) Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res 67: 5851-5858.
7. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
8. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, et al. (2008) Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 27: 3539-3545.
9. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, et al. (2011) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117: 1399-1408.
10. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, et al. (2008) PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 29: 284-288.
11. Herreros-Villanueva M, Gomez-Manero N, Muniz P, Garcia-Giron C, Coma del Corral MJ, (2011) PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. Mol Biol Rep 38: 1347-1351.
12. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, et al. (2012) Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 413: 1605-1611.
13. Iida S, Kato S, Ishiguro M, Matsuyama T, Ishikawa T, et al. (2012) PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett 3: 565-570.
14. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, et al. (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 6: e22769.
15. Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, et al. (2009) Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 219: 337-346.
16. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, et al. (2011) Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 11: 123.
17. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, et al. (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10: 534-541.
18. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, et al. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27: 1477-1484.
19. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, et al. (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15: 3184-3188.
20. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, et al. (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41: 1649-1654.
21. Whitehall VL, Rickman C, Bond CE, Ramsnes I, Greco SA, et al. (2012) Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 131: 813-820.
22. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
23. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664.
24. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
25. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, et al. (2013) A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62: 540-549.
26. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, et al. (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10: 558-565.
27. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, et al. (2012) Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367: 1596-1606.
28. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, et al. (2007) PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121: 1771-1778.
29. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, et al. (2012) Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 18: 2257-2268.
30. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, et al. (2012) KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS ONE 7: e38033.
31. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL, (2012) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23: 1518-1525.
32. Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, et al. (2011) PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr) 34: 523-531.
33. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, et al. (2008) Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 17: 1774-1780.
34. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, et al. (2013) Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol: doi: 10.1038/modpathol.2012.1240.
35. Walsh MD, Cummings MC, Buchanan DD, Dambacher WM, Arnold S, et al. (2008) Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res 14: 1692-1700.
36. Rosty C, Buchanan DD, Walsh MD, Pearson SA, Pavluk E, et al. (2012) Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am J Surg Pathol 36: 876-882.
37. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
38. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, et al. (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61: 847-854.
39. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, et al. (2006) Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19: 59-68.
40. Miyaki M, Iijima T, Yamaguchi T, Takahashi K, Matsumoto H, et al. (2007) Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121: 1627-1630.
41. Loboda A, Nebozhyn M, Cheng C, Vessey R, Huang P, et al. (2009) Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther 86: 92-96.
42. Zhao L, Vogt PK, (2010) Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9: 596-600.
43. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, et al. (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6069.